Metformin and vascular protection: A cardiologist's view

Diabetes and Metabolism

Volumn 29, Issue 4 II, 2003, Pages

  Libby, Peter ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; Metabolic syndrome; Metformin; Type 2 diabetes

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR SYSTEM; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; TREATMENT PLANNING; VASCULAR DISEASE; CARDIOLOGY; CARDIOVASCULAR DISEASE; METABOLIC SYNDROME X;

CARDIOLOGY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN;

EID: 0642372536     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(03)72796-7     Document Type: Review

References (25)

1. nd edition. Bethesda, MD: National Institutes of Health and national Institute of Diabetes and Digestive and Kidney Diseases, 233-55.
2. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
3. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2002, 25 (suppl. 1), S33-S49.
4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2002, 25, S5-S20.
5. American Association of Clinical Endocrinologists and the American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: the AACE System of intensive diabetes self-management - 2002 Update. Endocr Pract, 2002, 8 (suppl. 1), 40-82.
6. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation, 2002, 106, 2760-3.
7. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-9.
8. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation, 1999, 99, 216-23.
9. Bloomfield Rubins H, Davenport J, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation, 2001, 103, 2828-33.
10. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 2001, 357, 905-10.
11. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998, 351, 1755-62.
12. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA, 2001, 286, 1882-5.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
14. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000, 102, 21-7.
15. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-65.
16. Stratton IM, Adler Al, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J, 2000, 321, 405-12.
17. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Reviews, 1998, 6, 89-131.
18. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res, 1994, 30, 197-228.
19. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of "metformin-associated lactic acidosis". Diabetes Obes Metab, 2000, 2, 1-7.
20. Cryer DR, Mills DJ, Henry DH, Nicholas SP. The Comparative Outcomes Study of Metformin Intervention versus Conventional Approach: the COSMIC Approach Study. Diabetes, 2003, 52 (suppl. 1): A114 [Abstract 495P].
21. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy, 2002, 22, 924-9.
22. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs, 2002, 62, 1805-37.
23. Bailey CJ. New pharmacologic agents for diabetes. Curr Diab Rep, 2001, 1, 119-26.
24. Pearson TA, Smith SC, Poole-Wilson P. Cardiovascular specialty societies and the emerging global burden of cardiovascular disease. A call to action. Circulation, 1998, 97, 602-4.
25. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA, 2002, 287, 2570-81.